Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$15.65
+6.3%
$15.68
$11.09
$17.67
$1.85B0.891.43 million shs1.78 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$13.13
-1.0%
$13.21
$7.07
$15.43
$821.86M1.47641,371 shs2.23 million shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$0.75
-1.3%
$1.07
$0.45
$1.88
$168.67M1.841.37 million shs1.68 million shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.14
$1.22
$8.45
$45.46M1.5329,344 shs280 shs
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$0.38
$0.38
$0.26
$1.30
$67.96M0.747,701 shs29,800 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
-2.77%-3.16%-5.09%+10.10%-15.40%
Evolus, Inc. stock logo
EOLS
Evolus
-1.19%+5.07%-0.30%-0.75%+46.20%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
+3.27%+6.77%-30.06%-12.26%-44.46%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%-99.99%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.00%0.00%0.00%0.00%-48.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.9605 of 5 stars
4.51.00.03.91.13.34.4
Evolus, Inc. stock logo
EOLS
Evolus
3.8601 of 5 stars
3.52.00.03.51.82.50.6
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.8194 of 5 stars
3.42.00.04.71.82.50.0
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.00
Buy$26.4368.87% Upside
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$20.6056.89% Upside
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
2.80
Moderate Buy$7.65926.02% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/A

Current Analyst Ratings

Latest PYR, GOSS, NBRV, EOLS, and CPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2024
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
5/8/2024
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/8/2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00
5/6/2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
4/10/2024
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
4/5/2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$4.00
3/27/2024
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$29.00
3/27/2024
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00
3/22/2024
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
3/14/2024
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
3/14/2024
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$27.00
(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$398.20M4.64$2.19 per share7.16$3.30 per share4.74
Evolus, Inc. stock logo
EOLS
Evolus
$202.09M4.07N/AN/A($0.36) per share-36.47
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/A$0.28 per shareN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$14.63M4.65N/AN/A$0.07 per share5.43

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$71.41M$0.6125.667.110.8117.93%26.56%22.13%8/14/2024 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%8/7/2024 (Estimated)
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$179.82M-$1.39N/AN/AN/AN/A-944.79%-67.76%8/13/2024 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
-$24.74M-$0.11N/AN/A-233.18%-194.66%-68.91%N/A

Latest PYR, GOSS, NBRV, EOLS, and CPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Evolus, Inc. stock logo
EOLS
Evolus
-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 million
3/5/202412/31/2023
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.21-$0.21N/A-$0.21N/AN/A
2/28/2024Q4 2023
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$0.45$0.49+$0.04$0.67$105.78 million$110.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
2.88
2.68
Evolus, Inc. stock logo
EOLS
Evolus
N/A
2.33
2.10
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.14
5.94
5.94
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.26
0.86
0.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.41%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
11.00%
Evolus, Inc. stock logo
EOLS
Evolus
5.40%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
5.00%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
1.63%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
47.68%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
167118.01 million105.03 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
27362.59 million59.21 millionOptionable
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
135226.22 million214.91 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
3932.02 million31.49 millionNot Optionable
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
2,020178.88 million93.59 millionNot Optionable

PYR, GOSS, NBRV, EOLS, and CPRX Headlines

SourceHeadline
MedBright AI Investments Inc.MedBright AI Investments Inc.
baystreet.ca - May 2 at 12:53 PM
Progressive Planet provides results from its strength testsProgressive Planet provides results from its strength tests
canadianmanufacturing.com - May 2 at 12:53 PM
PyroGenesis announces positive results for green cement additive in recent testsPyroGenesis announces positive results for green cement additive in recent tests
proactiveinvestors.com - May 2 at 9:14 AM
PyroGenesis wins contract to supply Spanish aerospace firm with titanium metal powderPyroGenesis wins contract to supply Spanish aerospace firm with titanium metal powder
proactiveinvestors.com - April 30 at 9:37 AM
PyroGenesis Kicks Off New European Distribution Strategy with Contract to Supply Spanish Aerospace Entity with Titanium Metal PowderPyroGenesis Kicks Off New European Distribution Strategy with Contract to Supply Spanish Aerospace Entity with Titanium Metal Powder
markets.businessinsider.com - April 30 at 8:05 AM
PyroGenesis receives project milestone paymentsPyroGenesis receives project milestone payments
proactiveinvestors.com - April 25 at 9:23 AM
PyroGenesis partners with major steelmaker on plasma torch integrationPyroGenesis partners with major steelmaker on plasma torch integration
proactiveinvestors.com - April 24 at 9:44 AM
PyroGenesis Canada Inc.: PyroGenesis Contracts with Global Mining Supply Company to Examine Novel Use of Plasma in Decarbonization ProcessPyroGenesis Canada Inc.: PyroGenesis Contracts with Global Mining Supply Company to Examine Novel Use of Plasma in Decarbonization Process
finanznachrichten.de - April 17 at 1:05 PM
PyroGenesis Contracts with Global Mining Supply Company to Examine Novel Use of Plasma in ...PyroGenesis Contracts with Global Mining Supply Company to Examine Novel Use of Plasma in ...
bakersfield.com - April 17 at 1:05 PM
PyroGenesis to collaborate with global mining parts manufacturer to assess electric plasma torchesPyroGenesis to collaborate with global mining parts manufacturer to assess electric plasma torches
proactiveinvestors.com - April 17 at 9:06 AM
PyroGenesis Canada Inc.: PyroGenesis Announces That Lab Strength Tests Achieve 45% Above Target for Green Cement Additive ProductPyroGenesis Canada Inc.: PyroGenesis Announces That Lab Strength Tests Achieve 45% Above Target for Green Cement Additive Product
finanznachrichten.de - April 12 at 8:02 PM
PyroGenesis Canada Inc.: PyroGenesis Announces Block Sale of HPQ Silicon Inc. Shares to its President and CEOPyroGenesis Canada Inc.: PyroGenesis Announces Block Sale of HPQ Silicon Inc. Shares to its President and CEO
finanznachrichten.de - April 12 at 4:59 AM
Stocks in play: PyroGenesis Canada Inc.Stocks in play: PyroGenesis Canada Inc.
ca.finance.yahoo.com - April 11 at 12:30 PM
Constellium to trial PyroGenesis plasma burner technologyConstellium to trial PyroGenesis plasma burner technology
recyclingtoday.com - April 11 at 12:30 PM
PyroGenesis reports impressive strength test results for cement additive productPyroGenesis reports impressive strength test results for cement additive product
proactiveinvestors.com - April 11 at 8:44 AM
Progressive Planet Announces Superb Compressive Strength for New Low Carbon CementProgressive Planet Announces Superb Compressive Strength for New Low Carbon Cement
ca.finance.yahoo.com - April 11 at 7:30 AM
PyroGenesis partners with Constellium on aluminum remelting furnaces technologyPyroGenesis partners with Constellium on aluminum remelting furnaces technology
proactiveinvestors.com - April 10 at 8:51 AM
Constellium Paris: Constellium and PyroGenesis partner to advance plasma burner technology in aluminium melting processConstellium Paris: Constellium and PyroGenesis partner to advance plasma burner technology in aluminium melting process
finanznachrichten.de - April 10 at 8:51 AM
PyroGenesis and Constellium Sign Letter of Intent for Large-Scale Plasma Remelting FurnacesPyroGenesis and Constellium Sign Letter of Intent for Large-Scale Plasma Remelting Furnaces
markets.businessinsider.com - April 10 at 8:51 AM
PyroGenesis Canada Inc. (PYRGF) Q4 2023 Earnings Call TranscriptPyroGenesis Canada Inc. (PYRGF) Q4 2023 Earnings Call Transcript
seekingalpha.com - April 4 at 7:00 PM
PyroGenesis appoints capital markets expert to boardPyroGenesis appoints capital markets expert to board
proactiveinvestors.com - April 4 at 10:14 AM
PyroGenesis Canada Full Year 2023 Earnings: CA$0.16 loss per share (vs CA$0.19 loss in FY 2022)PyroGenesis Canada Full Year 2023 Earnings: CA$0.16 loss per share (vs CA$0.19 loss in FY 2022)
uk.finance.yahoo.com - April 3 at 7:56 AM
PyroGenesis eyes revenue growth from $29M backlog for its decarbonization solutionsPyroGenesis eyes revenue growth from $29M backlog for its decarbonization solutions
proactiveinvestors.com - April 2 at 11:22 AM
CPP Pension: 1 Move to Increase Your Payouts by $6,877 Per YearCPP Pension: 1 Move to Increase Your Payouts by $6,877 Per Year
ca.finance.yahoo.com - March 28 at 1:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Catalyst Pharmaceuticals logo

Catalyst Pharmaceuticals

NASDAQ:CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Evolus logo

Evolus

NASDAQ:EOLS
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Gossamer Bio logo

Gossamer Bio

NASDAQ:GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Nabriva Therapeutics logo

Nabriva Therapeutics

NASDAQ:NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
PyroGenesis Canada logo

PyroGenesis Canada

NASDAQ:PYR
PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada.